Sfoglia per Autore
Activity and toxicity of paclitaxel in pretreated metastatic penile cancer patients
2009 G.D. Lorenzo, G. Carteni, R. Autorino, A. Gonnella, S. Perdona, M. Ferro, N. Longo, P. Rescigno, F. Doria, A. Faiella, V. Altieri, G. Palmieri, C. Imbimbo, V. Mirone, S. De Placido
Matrix metalloproteinase-2 and -9 in the urine of prostate cancer patients
2010 A. Di Carlo, A. Mariano, D. Terracciano, M. Ferro, V. Montanaro, M. Marsicano, G. Di Lorenzo, V. Altieri, V. Macchia
Effects of the ErbB1/ErbB2 kinase inhibitor GW2974 on androgen-independent prostate cancer PC-3 cell line growth and NSE, chromogranin A and osteopontin content
2010 D. Terracciano, C. Mazzarella, A. Di Carlo, A. Mariano, M. Ferro, G. Di Lorenzo, A. Giordano, V. Altieri, S. De Placido, V. Macchia
Sipuleucel-T for prostate cancer: The immunotherapy era has commenced
2011 C. Buonerba, M. Ferro, G.D. Lorenzo
Phase II trial of cisplatin plus prednisone in docetaxel-refractory castration-resistant prostate cancer patients
2011 C. Buonerba, P. Federico, C. D'Aniello, P. Rescigno, C. Cavaliere, L. Puglia, M. Ferro, V. Altieri, S. Perdona, S. De Placido, G.D. Lorenzo
Inhibitory effect of standardized Cannabis sativa extract and its ingredient cannabidiol on rat and human bladder contractility
2011 R. Capasso, G. Aviello, F. Borrelli, B. Romano, M. Ferro, L. Castaldo, V. Montanaro, V. Altieri, A.A. Izzo
Soluble interleukin-6 receptor to interleukin-6 (sIL-6r/IL-6) ratio in serum as a predictor of high Gleason sum at radical prostatectomy
2011 D. Terracciano, D. Bruzzese, M. Ferro, R. Autorino, G. Di Lorenzo, C. Buonerba, A. Mariano, V. Macchia, V. Altieri, A. Di Carlo
Paclitaxel in pretreated metastatic penile cancer: Final results of a phase 2 study
2011 G. Di Lorenzo, P. Federico, C. Buonerba, N. Longo, G. Carten, R. Autorino, S. Perdon, M. Ferro, P. Rescigno, C. D'Aniello, E. Matano, V. Altieri, G. Palmieri, C. Imbimbo, S. De Placido, V. Mirone
Erratum to: Phase II trial of cisplatin plus prednisone in docetaxel-refractory castration-resistant prostate cancer patients
2011 C. Buonerba, P. Federico, C. D'Aniello, P. Rescigno, C. Cavaliere, L. Puglia, M. Ferro, V. Altieri, S. Perdona, S. De Placido, G. Di Lorenzo
Phase II study of docetaxel re-treatment in docetaxel-pretreated castration-resistant prostate cancer
2011 G. Di Lorenzo, C. Buonerba, A. Faiella, P. Rescigno, M. Rizzo, R. Autorino, S. Perdona, N. Riccardi, S. Scagliorini, F. Scognamiglio, D. Masala, M. Ferro, G. Palmieri, M. Aieta, A. Marinelli, V. Altieri, S. De Placido, G. Carteni
Chondroitin sulphate enhances the antitumor activity of gemcitabine and mitomycin-C in bladder cancer cells with different mechanisms
2012 M. Ferro, G. Giuberti, S. Zappavigna, S. Perdona, G. Facchini, P. Sperlongano, S. Porto, G. Di Lorenzo, C. Buonerba, A. Abbruzzese, V. Altieri, M. Caraglia
Predicting prostate biopsy outcome: Prostate health index (phi) and prostate cancer antigen 3 (PCA3) are useful biomarkers
2012 M. Ferro, D. Bruzzese, S. Perdona, C. Mazzarella, A. Marino, A. Sorrentino, A. Di Carlo, R. Autorino, G. Di Lorenzo, C. Buonerba, V. Altieri, A. Mariano, V. Macchia, D. Terracciano
How to carry out retrospective studies in metastatic renal cell cancer: Two caveats that should be avoided
2012 G. Di Lorenzo, M. Ferro, C. Buonerba
Sipuleucel-T (Provenge®) for castration-resistant prostate cancer
2012 G. Di Lorenzo, M. Ferro, C. Buonerba
Preoperative insulin-like growth factor-binding protein-3 (IGFBP-3) blood level predicts gleason sum upgrading
2012 D. Terracciano, D. Bruzzese, M. Ferro, C. Mazzarella, G. Di Lorenzo, V. Altieri, A. Mariano, V. Macchia, A. Di Carlo
Cisplatin and 5-fluorouracil in inoperable, stage IV squamous cell carcinoma of the penis
2012 G. Di Lorenzo, C. Buonerba, P. Federico, S. Perdona, M. Aieta, P. Rescigno, C. D'Aniello, L. Puglia, A. Petremolo, M. Ferro, A. Marinelli, G. Palmieri, G. Sonpavde, V. Mirone, S. De Placido
Calcitriol: A better option than vitamin D in denosumab-treated patients with kidney failure?
2013 C. Buonerba, M. Caraglia, S. Malgieri, F. Perri, D. Bosso, P. Federico, M. Ferro, M. Rizzo, G. Palmieri, G. Di Lorenzo
Prostate health index (phi) and prostate cancer antigen 3 (PCA3) significantly improve diagnostic accuracy in patients undergoing prostate biopsy
2013 S. Perdona, D. Bruzzese, M. Ferro, R. Autorino, A. Marino, C. Mazzarella, G. Perruolo, M. Longo, R. Spinelli, G. Di Lorenzo, A. Oliva, M. De Sio, R. Damiano, V. Altieri, D. Terracciano
Combined magnetic resonance spectroscopy and dynamic contrast-enhanced imaging for prostate cancer detection
2013 S. Perdona, G. Di Lorenzo, R. Autorino, C. Buonerba, M. De Sio, S.V. Setola, R. Fusco, F.M. Ronza, M. Caraglia, M. Ferro, A. Petrillo
Peg-filgrastim and cabazitaxel in prostate cancer patients
2013 G. Di Lorenzo, C. D'Aniello, C. Buonerba, P. Federico, P. Rescigno, L. Puglia, M. Ferro, D. Bosso, C. Cavaliere, G. Palmieri, G. Sonpavde, S. De Placido
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile